Escitalopram-induced hepatitis: A case report

Table 1 C-reactive protein and liver test levels (D0: Day when escitalopram was withdrawn)

Date	C-reactive protein (mg/L)	Total bilirubin (µmol/L)	Conjugated bilirubin (µmol/L)	Unconjugated bilirubin (µmol/L)	Alanine transa-minase (IU/L)
D - 22	< 5.00	4
D0	8.20	101	65	36	80
D + 1	7.80	109	66	43	77
D + 3	15.00	117	69	48	72
D + 4	13.90	115	71	44	69
D + 16		84	46	38	58
D + 20		50	24	26
D + 29	6.90	25	11	14	43

Table 2 Search criteria in Vigibase^® (characterization of hepatitis or cholestasis)

Adverse drug reactions list for extraction	The minimal set of data needed for extraction
Cholestasis and jaundice (HLT); Hepatic and hepatobiliary disorders NEC (HLT); Hepatic enzymes and function abnormalities (HLT); Hepatobiliary signs and symptoms (HLT); Cholestatic liver injury (PT); Drug-induced liver injury (PT); Hepatitis (PT); Hepatitis acute (PT); Hepatitis toxic (PT); Hepatocellular injury (PT); Hepatotoxicity (PT)	Patient age above 18 years old; Patient gender specified in the ICSR
HLT and PT from the MedDRA® hierarchy

HLT: High-level term; PT: Preferred term; ICSR: Individual case safety report; NEC: Necrotizing enterocolitis.

Table 3 Reporting odds ratio of acute hepatitis and cholestasis in Vigibase^® in patients receiving escitalopram

	OR	95% CI	P value
Acute hepatitis	1.938	1.186-3.166	0.0083
Cholestasis	1.866	1.279-2.724	0.0012

OR: Odds ratio; CI: Confidence interval.